US Bancorp DE Sells 1,898 Shares of GRAIL, Inc. (NASDAQ:GRAL)

US Bancorp DE reduced its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 25.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,579 shares of the company’s stock after selling 1,898 shares during the period. US Bancorp DE’s holdings in GRAIL were worth $142,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Sessa Capital IM L.P. bought a new position in shares of GRAIL during the 4th quarter valued at approximately $53,550,000. Baker BROS. Advisors LP purchased a new stake in shares of GRAIL during the 4th quarter valued at approximately $29,098,000. Jacobs Levy Equity Management Inc. purchased a new stake in GRAIL in the 4th quarter worth approximately $18,209,000. AQR Capital Management LLC purchased a new stake in GRAIL in the 4th quarter worth approximately $14,828,000. Finally, Wealthquest Corp purchased a new stake in GRAIL in the 1st quarter worth approximately $18,247,000.

Insider Buying and Selling

In related news, CFO Aaron Freidin sold 8,000 shares of the business’s stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $38.93, for a total transaction of $311,440.00. Following the sale, the chief financial officer owned 286,020 shares of the company’s stock, valued at $11,134,758.60. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Chun R. Ding sold 339,800 shares of the business’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total transaction of $16,830,294.00. Following the sale, the insider directly owned 3,305,055 shares in the company, valued at $163,699,374.15. The trade was a 9.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 357,492 shares of company stock valued at $17,645,718 over the last quarter. Corporate insiders own 1.85% of the company’s stock.

GRAIL Stock Up 0.8%

Shares of GRAIL stock opened at $32.43 on Friday. The firm has a market cap of $1.17 billion, a PE ratio of -2.47 and a beta of 3.26. GRAIL, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99. The company’s fifty day simple moving average is $40.12 and its two-hundred day simple moving average is $36.30.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). The company had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. As a group, sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group raised their price objective on shares of GRAIL from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.